DrySyn OCTO parallel synthesizer helps improve workflow in early stage discovery chemistry

Asynt reports on how a DrySyn OCTO 8-position parallel synthesizer has benefited early stage discovery chemistry at Cancer Research UK (Cambridge, UK). Designed to work with any hotplate stirrer, the DrySyn Octo has enabled the CRUK Therapeutic Discovery Laboratories to increase the productivity of their small-scale synthetic reactions.

Dr Peter Blencowe, a senior scientist at the CRUK Therapeutic Discovery Laboratories commented “We have used the DrySyn OCTO to perform a variety of heterogeneous catalysis reactions under nitrogen to eliminate formation of side products. Using DrySyn OCTO – parallel reactions are very easy to set up saving time on the degassing and space on the heating arrangement required. We all like the unit and it has particularly helped us improve workflow when tasked with doing arrays of heated reactions in early discovery chemistry”.

The Asynt DrySyn OCTO 8-position parallel synthesizer is an easy-to-use entry-level product for chemists wishing to conduct synthetic reactions under an inert atmosphere with temperature control, reflux and powerful magnetic stirring. The compact DrySyn OCTO parallel synthesizer accommodates low cost consumable reaction tubes each with a working volume of 5-6 ml. The large surface area of these glass reaction tubes enables the DrySyn OCTO to be used for air cooled gentle reflux reactions. Up to 3 DrySyn OCTO units can be employed together on any standard magnetic hotplate stirrer, using a DrySyn MULTI baseplate. In this OCTO+ configuration users can perform 24 parallel reactions in a very small space. Gas tight closure on each tube connection enables reactions under inert atmospheres to be carried out using the DrySyn OCTO. Additions or reaction sampling can be made whilst under inert conditions using a syringe.  The unit uses low cost easily replaceable consumable septum’s.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Asynt. (2019, June 17). DrySyn OCTO parallel synthesizer helps improve workflow in early stage discovery chemistry. News-Medical. Retrieved on May 04, 2024 from https://www.news-medical.net/news/20180406/DrySyn-OCTO-parallel-synthesizer-helps-improve-workflow-in-early-stage-discovery-chemistry.aspx.

  • MLA

    Asynt. "DrySyn OCTO parallel synthesizer helps improve workflow in early stage discovery chemistry". News-Medical. 04 May 2024. <https://www.news-medical.net/news/20180406/DrySyn-OCTO-parallel-synthesizer-helps-improve-workflow-in-early-stage-discovery-chemistry.aspx>.

  • Chicago

    Asynt. "DrySyn OCTO parallel synthesizer helps improve workflow in early stage discovery chemistry". News-Medical. https://www.news-medical.net/news/20180406/DrySyn-OCTO-parallel-synthesizer-helps-improve-workflow-in-early-stage-discovery-chemistry.aspx. (accessed May 04, 2024).

  • Harvard

    Asynt. 2019. DrySyn OCTO parallel synthesizer helps improve workflow in early stage discovery chemistry. News-Medical, viewed 04 May 2024, https://www.news-medical.net/news/20180406/DrySyn-OCTO-parallel-synthesizer-helps-improve-workflow-in-early-stage-discovery-chemistry.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Industry & academia combine to support synthesis of squaric acid monoamides as building blocks for drug discovery